Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.24.2.u1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Income Statement [Abstract]        
Research and development (“R&D”) expenses, net $ 6,897 $ 3,818 $ 11,002 $ 8,382
General and administrative expenses 2,828 2,255 5,508 3,899
Operating loss 9,725 6,073 16,510 12,281
Other income (2,017) (90) (2,105) (181)
Interest expenses 13 745 863 1,310
Income from change in fair value of Private Placement Warrants (11,868) (3,858)
Finance expense (income), net (329) (325) 1,436 (652)
Loss (income) before tax (4,476) 6,403 12,846 12,758
Tax expenses 5 8 10 14
Net loss (income) $ (4,471) $ 6,411 $ 12,856 $ 12,772
Basic loss (earnings) per share of Common Stock (in Dollars per share) $ (0.01) $ 0.12 $ 0.19 $ 0.31
Diluted loss per share of Common Stock (in Dollars per share) $ 0.07 $ 0.12 $ 0.19 $ 0.31
Weighted average number of shares used in computing basic loss (earnings) per share of Common Stock (in Shares) 69,809,421 51,552,923 66,059,510 41,860,338
Weighted average number of shares used in computing diluted loss per share of Common Stock (in Shares) 107,501,932 51,552,923 66,059,510 41,860,338